Researchers map pathways to protective antibodies for an HIV vaccine

March 15, 2017
Top view of a model of a broadly-neutralizing HIV antibody (green) binding to its target (gray). Credit: M. Bonsignori et al., Science Translational Medicine (2017)

A Duke Health-led research team has described both the pathway of HIV protective antibody development and a synthetic HIV outer envelope mimic that has the potential to induce the antibodies with vaccination.

"A goal for an HIV-1 vaccine is to induce broadly neutralizing ," said senior author Barton F. Haynes, M.D., director of the Duke Human Vaccine Institute (DHVI). "One strategy for the induction of these desirable antibodies is to find a way to develop a small portion of the envelope's structure that these desired antibodies recognize - something we have now shown is possible."

In the first of two papers published online March 15 in Science Translational Medicine, Haynes and colleagues - including lead author Mattia Bonsignori, M.D. of DHVI—traced a series of events that led to the development of broadly in an HIV infected person over the course of five years.

The researchers found that the infected person's immune system responded to the virus with unusual, cooperative efforts between different B-cell lineages to induce broadly neutralizing antibodies. The antibody development process also involved acquisition of a rare genetic change critical for protective antibody activity.

In a second paper in the same edition of Science Translational Medicine, a team at Memorial Sloan Kettering Cancer Center, led by Samuel Danishefsky, Ph.D., used that blueprint to build a synthetic molecule that would mimic the HIV site targeted in infection. They also tested if the molecule could induce similar antibodies in the vaccination of a non-human primate.

The immunogen mimics a precise region of the virus where certain bind to generate an immune attack. The synthetic immunogen precisely mimics this site, and in non-human primate vaccination studies, can induce antibodies to this critical position.

The researchers at Duke, including lead author S. Munir Alam, Ph.D., report that the synthetic mimic induced antibodies targeted at the site much more quickly than what was observed in the original HIV-infected person.

Researchers map pathways to protective antibodies for an HIV vaccine. Credit: Shawn Rocco/Duke Health

"We have known that there is an Achilles' heel on the envelope of the virus that the right kind of antibodies target," Haynes said. "There is not just one spot, but several. An effective vaccine would need to target more than one of them to assure that the immune system is equipped with the weapons it needs to fight the virus through all of its mutations."

A third study from the DHVI, published Feb. 28 in the journal Cell Reports, demonstrated that macaques could indeed be vaccinated with an envelope of HIV and made antibodies to envelope sugar molecules. The researchers, led by Kevin O. Saunders, Ph.D., immunized macaques over a three-year period, and found that after this long duration of immunization, macaques made antibodies targeted at a broadly neutralizing antibody binding site containing sugars.

Haynes said all three studies support the concept of designing vaccine candidates that mimic critical regions of HIV. He said the goal is to combine all multiple HIV components that elicit the protective antibodies into one vaccine that could be tested in humans.

Explore further: Scientists identify immunological profiles of people who make powerful HIV antibodies

More information: "Staged induction of HIV-1 glycan–dependent broadly neutralizing antibodies," Science Translational Medicine, stm.sciencemag.org/lookup/doi/ … scitranslmed.aai7514

Related Stories

Scientists identify immunological profiles of people who make powerful HIV antibodies

July 29, 2016
One of the main mysteries confounding development of an HIV vaccine is why some people infected with the virus make the desired antibodies after several years, but a vaccine can't seem to induce the same response.

Researchers find alternative pathways to HIV antibodies

May 4, 2016
The immune system appears to hamper an investigational vaccine from inducing antibodies that protect against HIV infection, but there may be ways to overcome this impediment, according to research led by the Duke Human Vaccine ...

Mechanism found for development of protective HIV antibodies

July 24, 2014
Scientists at Duke Medicine have found an immunologic mechanism that makes broadly neutralizing antibodies in people who are HIV-1 infected.

Researchers unravel pathways of potent antibodies that fight HIV infection

March 3, 2016
One of the most crucial and elusive goals of an effective HIV vaccine is to stimulate antibodies that can attack the virus even as it relentlessly mutates.

New artificial protein mimics a part of the HIV outer coat

October 22, 2013
A team of scientists at Duke Medicine and Memorial Sloan-Kettering Cancer Center has created an artificial protein coupled with a sugar molecule that mimics a key site on the outer coat of HIV where antibodies can bind to ...

Human mode of responding to HIV vaccine is conserved from monkeys

January 16, 2015
The antibody response from an HIV vaccine trial in Thailand was made possible by a genetic trait carried over in humans from an ancient ancestry with monkeys and apes, according to a study led by Duke Medicine researchers.

Recommended for you

New injectable antiretroviral treatment proved to be as effective as standard oral therapy

August 3, 2017
Intramuscularly administered antiretroviral therapy (ART) may be as effective for HIV treatment as current oral therapies. This is the main conclusion of a Phase II clinical trial carried out by 50 research centers around ...

Research finds home-based kit would increase HIV testing

July 31, 2017
Research led by William Robinson, PhD, Associate Research Professor of Behavioral & Community Health Sciences at LSU Health New Orleans School of Public Health, has found that 86% of heterosexuals who are at high risk for ...

Scientists divulge latest in HIV prevention

July 25, 2017
A far cry from the 1990s "ABC" campaign promoting abstinence and monogamy as HIV protection, scientists reported on new approaches Tuesday allowing people to have all the safe sex they want.

Girl's HIV infection seems under control without AIDS drugs

July 24, 2017
A South African girl born with the AIDS virus has kept her infection suppressed for more than eight years after stopping anti-HIV medicines—more evidence that early treatment can occasionally cause a long remission that, ...

Meds by monthly injection might revolutionize HIV care (Update)

July 24, 2017
Getting a shot of medication to control HIV every month or two instead of having to take pills every day could transform the way the virus is kept at bay.

Candidate AIDS vaccine passes early test

July 24, 2017
The three-decade-old quest for an AIDS vaccine received a shot of hope Monday when developers announced that a prototype triggered the immune system in an early phase of human trials.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.